Tulay Kus

11PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsProbability theoryPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 28, 2026
Optimal Treatment Strategies for Pulmonary Large Cell Neuroendocrine Carcinoma Based on Molecular Subtypes.

Hakan Yücel, Tülay Kuş, Sibel Cangi

|Aug 28, 2025
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG).

Ali Kalem, Tulay Kus, Savas Gokcek

|Jul 25, 2024
The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey.

Hacı Arak, Bahtiyar Sahinoğlu, Tulay Kus

|Jan 10, 2024
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials.

Tulay Kus, Irfan Cicin

|Jun 09, 2023
Is the "P-value" Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?

Tulay Kus, Gokmen Aktas, Irfan Cicin

|Jun 22, 2022
Correction to : Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?

Tulay Kus, Gokmen Aktas

Pageof 2

Frequent Collaborators

3 joint publications

Gokmen Aktas

2 joint publications

Havva Yeşil Çınkır

2 joint publications

Hacı Arak

1 joint publications

Ali Alkan